We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'. The phenomenon has swept the US and overseas, as people - including ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...